Immune checkpoint inhibitors of the PD-1/PD-L1 axis (nivolumab, pembrolizumab, or atezolizumab) represent a major advance in lung cancer treatment and have improved the overall survival of patients with NSCLC. This evidence concerns the gene CD274 and lung cancer.